Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

74.10
+0.33000.45%
Volume:581.87K
Turnover:42.99M
Market Cap:10.30B
PE:-10.32
High:74.65
Open:73.51
Low:73.21
Close:73.77
52wk High:88.31
52wk Low:47.22
Shares:139.02M
Float Shares:138.02M
Volume Ratio:0.79
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1827
EPS(LYR):-6.5400
ROE:-572.15%
ROA:-28.09%
PB:-59.38
PE(LYR):-11.33

Loading ...

S&P 500 Futures Rise In Premarket Trading; Western Digital, Agilent Technologies Lead

Dow Jones
·
Jun 16

Cytokinetics CEO Robert I. Blum sells 7,500 common shares for $528,450

Reuters
·
Jun 16

Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares worth $237,930

Reuters
·
Jun 10

Cytokinetics posts GALACTIC-HF presentation on serum magnesium outcomes in HFrEF

Reuters
·
Jun 09

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

THOMSON REUTERS
·
Jun 08

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 06

Cytokinetics director Edward M. Kaye MD disposes of 2,933 common shares for $223,142.97

Reuters
·
Jun 02

Cytokinetics EVP, Chief Commercial Officer Andrew Callos disposes of 15,000 common shares for $1.11 million

Reuters
·
Jun 02

Cytokinetics director B. Lynne Parshall disposes of USD 370,400 in common shares

Reuters
·
Jun 02

Cytokinetics - Myqorzo Launched in Germany Following European Commission Approval in February 2026

THOMSON REUTERS
·
Jun 01

Cytokinetics Launches Myqorzo® (Aficamten) in European Union, With First Commercial Availability in Germany

THOMSON REUTERS
·
Jun 01

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

GlobeNewswire
·
Jun 01

Cytokinetics Announces Launch of Myqorzo (Aficamten) in Germany for Symptomatic Obstructive Hypertrophic Cardiomyopathy

THOMSON REUTERS
·
Jun 01

Cytokinetics CEO Makes Major Move With Fresh Stock Sale

TIPRANKS
·
May 29

Cytokinetics CEO Robert I. Blum sells 7,500 shares for $579,075

Reuters
·
May 29

Cytokinetics Shareholders Reinforce Board and Governance Frameworks

TIPRANKS
·
May 28

Cytokinetics shareholders elect three Class I directors at annual meeting

Reuters
·
May 28

Cytokinetics to Participate in June Investor Conferences

GlobeNewswire
·
May 28

Top Cytokinetics Executive Makes Notable Move With Fresh Stock Sale

TIPRANKS
·
May 21

Cytokinetics EVP R&D Malik sells 3,500 shares for $264,915‬

Reuters
·
May 21